Outlook Therapeutics Inc. (NASDAQ:OTLK) does about 3.77M shares in volume on a normal day but saw 4110068 shares change hands in Tuesday trading. The company now has a market cap of 82.44M USD. Its current market price is $0.62, marking a decrease of -6.08% compared to the previous close of $0.66. The 52 week high reached by this stock is $1.95 whilst the lowest price level in 52 weeks is $0.50. The script in recent trading has seen the stock touch a high of $0.634 and a low of $0.58.

Outlook Therapeutics Inc. (OTLK) has a 20-day trading average at $1.2002 and the current price is -68.21% off the 52-week high compared with 24.23% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.3213 and its 200-day simple moving average is $0.9877. If we look at the stock’s price movements over the week, volatility stands at 12.21%, which decreases to 9.66% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 21.23 to suggest the stock is oversold.

5 analysts observing the Outlook Therapeutics Inc. (OTLK) stock have set the 12-month price targets for the company’s shares at between $3.25 and $8.00. The median price target is 87.6% away from the current levels at $5.00.

FactSet Research has provided data showing that 5 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 5 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on September 11, 2019 when Ladenburg Thalmann initiated the stock to “Buy” and issued a price target of $9.

The current price level is -49.81%, -53.60%, and -37.40% away from its SMA20, SMA50, and SMA200 respectively, with the OTLK price moving above the 50-day SMA on September 01. Outlook Therapeutics Inc. (OTLK) stock is down -51.57% over the week and -55.40% over the past month. Its price is 5.07% year-to-date and -59.75% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.11 below consensus estimates by $0. The company’s next earnings report is expected on 12/16/2020, with forecasts estimating quarterly EPS at -$0.08 and -$0.48 for whole year. OTLK’s earnings per share are forecast to grow by 61.30% this year and 27.10% over next year. Expected sales for next quarter are $320k, which analysts say will come at $130k for the current fiscal year and next year at $510k. In addition, estimates put the company’s current quarterly revenue at an average of $130k.

Its 12-month price target is $5.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $3.25, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $8.00.

The company has a return on investment of 2576.60% and return on equity of 347.60%. The beta has a value of 0.08. Price to book ratio is 5.17 and price to sales ratio is 13.97.

According to a U.S. Securities and Exchange Commission filing, Vanguard Extended Market Index Fu has added its position in Outlook Therapeutics Inc. (OTLK) to 337,342 shares, mirroring a recent increase by 9.69%. Vanguard Extended Market Index Fu added 29800.0 shares of Outlook Therapeutics Inc. common stock bringing its total worth to about $0.46 million at the end of recent close, SEC documents show. Vanguard Extended Market Index Fu isn’t the only investment manager who changed stakes and is followed by Vanguard Total Stock Market Index, which sold off 0.0 shares to end up with 223,704 shares worth $0.3 million. Fidelity Nasdaq Composite Index F cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.04% position in Outlook Therapeutics Inc. thanks to 49059.0 shares amounting to $66720.0.